The Technical Analyst
Graf Acquisition Corp. IV [GFOR]
Exchange: NYSE Sector: Financial Services Industry: Shell Companies
Graf Acquisition Corp. IV Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.06% $8.30
America/New_York / 29 sep 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 86.10 mill |
| EPS: | -0.0100 |
| P/E: | -830.00 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 10.37 mill |
| Avg Daily Volume: | 0.117 mill |
| RATING 2023-09-29 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -830.00 | sector: PE 9.91 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -830.00 | industry: PE -11.98 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 7.63 - 8.97 ( +/- 8.04%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-13 | Park Sangwoo | Sell | 2 500 000 | Common Stock |
| 2023-12-07 | Song Paul Y. | Buy | 76 | Common Stock |
| 2023-12-06 | Song Paul Y. | Buy | 75 | Common Stock |
| 2023-12-05 | Song Paul Y. | Buy | 105 | Common Stock |
| 2023-12-04 | Song Paul Y. | Buy | 163 | Common Stock |
| INSIDER POWER |
|---|
| 2.32 |
| Last 40 transactions |
| Buy: 5 254 482 | Sell: 4 694 762 |
Forecast:
01:40 - $9.91
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.30 (5.06% ) |
| Volume | 0.119 mill |
| Avg. Vol. | 0.117 mill |
| % of Avg. Vol | 101.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GFOR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GFOR
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in The Woodlands, Texas.
Latest Press Releases
2023-09-22 08:31:00 - Press Release
Graf Acquisition Corp. Iv Announces Adjournment Of Special Meeting To Approve Business Combination With Nkgen Biotech, Inc. To September 25, 2023
The woodlands, texas , sept. 22, 2023 /prnewswire/ -- graf acquisition corp. iv (nyse: gfor, gfor.u, gfor ws) (the "company" or "graf"), announced today that on september 20, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "business combination") with nkgen biotech, inc. ("nkgen" and such special meeting, the "special meeting").
2023-09-14 09:00:00 - Press Release
Graf Acquisition Corp. Iv Announces Adjournment Of Special Meeting To Approve Business Combination With Nkgen Biotech, Inc. To September 20, 2023
The woodlands, texas , sept. 14, 2023 /prnewswire/ -- graf acquisition corp. iv (nyse: gfor, gfor.u, gfor ws) (the "company" or "graf"), announced today that on september 13, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "business combination") with nkgen biotech, inc. ("nkgen" and such special meeting, the "special meeting").
2023-09-11 11:08:00 - Press Release
Graf Acquisition Corp. Iv Announces Adjournment Of Special Meeting To Approve Business Combination With Nkgen Biotech, Inc. To September 13, 2023
The woodlands, texas , sept. 11, 2023 /prnewswire/ -- graf acquisition corp. iv (nyse: gfor, gfor.u, gfor ws) (the "company" or "graf"), announced today that on september 8, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "business combination") with nkgen biotech, inc. ("nkgen" and such special meeting, the "special meeting").
2023-08-30 07:00:00 - Press Release
Graf Acquisition Corp. Iv Announces Intent To Adjourn Special Meeting To Approve Business Combination With Nkgen Biotech, Inc. To September 8, 2023
The woodlands, texas, aug. 30, 2023 (globe newswire) -- graf acquisition corp. iv (nyse: gfor, gfor-un, gfor-wt) (the “company” or “graf”), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the “business combination”) with nkgen biotech, inc. (“nkgen” and such special meeting, the “special meeting”), which is scheduled to occur at 10:00 a.m., eastern time, on august 30, 2023, and to reconvene the special meeting at 10:30 a.m., eastern time, on september 8, 2023. the special meeting will still be held virtually at https://www...
2023-08-24 08:00:00 - Press Release
Nkgen Biotech, Inc. Announces First Patient Dosed In Phase I Clinical Trial Of Snk02, Allogeneic Nk Cell Therapy Product Candidate, For The Treatment Of Solid Tumors
Santa ana, calif., aug. 24, 2023 (globe newswire) -- nkgen biotech, inc. (“nkgen” or the “company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and car-nk natural killer (“nk”) cell therapies, today announced the first patient has been dosed in a phase i, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived nk cell therapy (“snk02”). in october 2022, the food and drug administration allowed nkgen's phase i snk02 clinical trial to proceed per its investigational new drug application. nkgen previously announced a proposed business combination with graf acquisition corp...
Latest News
2021-07-09 08:39:00 - Business Wire
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
2021-06-02 16:46:00 - Business Wire
Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering